Vaccines and Antibodies
through artificial intelligence
Evaxion discovers and develops novel prophylactic vaccines and therapeutic antibodies with a high medial need against serious infectious diseases. EDEN Technology, Evaxions’ in silico antigen discovery platform identifies proteins that elicit a highly and broadly immune response, solving one of the greatest challenges in vaccine discovery.
Evaxion has an entrepreneurial and dedicated management team, supported by a Board and a Scientific Advisory Board (SAB) with international Key Opinion Leaders within bioinformatics, vaccine development and biotech business.
EDEN Technology is an in silico antigen discovery platform that integrates big data, artificial intelligence and supercomputing. The key strength of EDEN is the ability to identify novel antigens, which cannot be identified with current technologies that elicit a highly and broadly protective immune response.
Evaxion is building a unique pipeline of prophylactic vaccines and therapeutic antibodies with a high medical need against infectious diseases.
Evaxion is focused on the development of its lead candidate EVX001, a highly and broadly protective vaccine against S. aureus.
PLEASE CONTACT EVAXION BIOTECH
Ole Maaloesvej 3
2200 Copenhagen N, Denmark
Sabine Molleskov Pedersen
© Copyright 2015 Evaxion Biotech All rights reserved